[F]-2′ -Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (F-FMAU) in Prostate Cancer: Initial Preclinical Observations
We hypothesized that imaging-based assessment of cellular proliferation in prostate cancer may improve tumor characterization. We therefore evaluated the biodistribution and effect of androgen on tumor uptake of the cellular proliferation imaging marker [ 18 F]-2'-fluoro-5-methyl-1-beta-D-arabi...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publications
2012-09-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.2310/7290.2012.00004 |
| _version_ | 1797283821536673792 |
|---|---|
| author | Hossein Jadvar Li-Peng Yap Ryan Park Zibo Li Kai Chen Lindsey Hughes Aida Kouhi Peter Conti |
| author_facet | Hossein Jadvar Li-Peng Yap Ryan Park Zibo Li Kai Chen Lindsey Hughes Aida Kouhi Peter Conti |
| author_sort | Hossein Jadvar |
| collection | DOAJ |
| description | We hypothesized that imaging-based assessment of cellular proliferation in prostate cancer may improve tumor characterization. We therefore evaluated the biodistribution and effect of androgen on tumor uptake of the cellular proliferation imaging marker [ 18 F]-2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil ( 18 F-FMAU) in xenograft mouse models of human prostate cancer. Castrated and noncastrated athymic male mice were implanted with androgen-independent PC3 and androgen-sensitive CWR22 human prostate cancer cells. Dynamic micro–positron emission tomography (PET)/computed tomography was performed for 1 hour followed by 10-minute static scans at 2 and 3 hours. Animals were sacrificed after imaging for biodistribution studies and immunohistochemical staining of tumors for androgen receptor and Ki-67/MIB expression. 18 F-FMAU uptake was significantly higher in all major organs of the castrated animals in comparison with noncastrated mice, with the highest uptake in liver and the lowest uptake in muscle and bone. When compared to PC3 tumors, CWR22 xenografts showed significantly higher tumor to muscle (2.56 ± 0.30 vs 1.99 ± 0.30, p 5.008) and tumor to liver (1.72 ± 0.12 vs 1.26 ± 0.17, p = .0003) uptake ratios in the noncastrated animal at the 3-hour time point. Androgen receptor and Ki-67/MIB expressions were higher in CWR22 than in PC3 xenografts. Our initial preclinical observations suggest that there may be an association between androgen signaling and thymidine metabolism and that 18 F-FMAU PET may be useful in prostate tumor characterization. |
| first_indexed | 2024-03-07T17:37:22Z |
| format | Article |
| id | doaj.art-d1b9592e588e4700b6ac1dbcfc133c59 |
| institution | Directory Open Access Journal |
| issn | 1536-0121 |
| language | English |
| last_indexed | 2024-03-07T17:37:22Z |
| publishDate | 2012-09-01 |
| publisher | SAGE Publications |
| record_format | Article |
| series | Molecular Imaging |
| spelling | doaj.art-d1b9592e588e4700b6ac1dbcfc133c592024-03-02T16:40:12ZengSAGE PublicationsMolecular Imaging1536-01212012-09-011110.2310/7290.2012.0000410.2310_7290.2012.00004[F]-2′ -Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (F-FMAU) in Prostate Cancer: Initial Preclinical ObservationsHossein JadvarLi-Peng YapRyan ParkZibo LiKai ChenLindsey HughesAida KouhiPeter ContiWe hypothesized that imaging-based assessment of cellular proliferation in prostate cancer may improve tumor characterization. We therefore evaluated the biodistribution and effect of androgen on tumor uptake of the cellular proliferation imaging marker [ 18 F]-2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil ( 18 F-FMAU) in xenograft mouse models of human prostate cancer. Castrated and noncastrated athymic male mice were implanted with androgen-independent PC3 and androgen-sensitive CWR22 human prostate cancer cells. Dynamic micro–positron emission tomography (PET)/computed tomography was performed for 1 hour followed by 10-minute static scans at 2 and 3 hours. Animals were sacrificed after imaging for biodistribution studies and immunohistochemical staining of tumors for androgen receptor and Ki-67/MIB expression. 18 F-FMAU uptake was significantly higher in all major organs of the castrated animals in comparison with noncastrated mice, with the highest uptake in liver and the lowest uptake in muscle and bone. When compared to PC3 tumors, CWR22 xenografts showed significantly higher tumor to muscle (2.56 ± 0.30 vs 1.99 ± 0.30, p 5.008) and tumor to liver (1.72 ± 0.12 vs 1.26 ± 0.17, p = .0003) uptake ratios in the noncastrated animal at the 3-hour time point. Androgen receptor and Ki-67/MIB expressions were higher in CWR22 than in PC3 xenografts. Our initial preclinical observations suggest that there may be an association between androgen signaling and thymidine metabolism and that 18 F-FMAU PET may be useful in prostate tumor characterization.https://doi.org/10.2310/7290.2012.00004 |
| spellingShingle | Hossein Jadvar Li-Peng Yap Ryan Park Zibo Li Kai Chen Lindsey Hughes Aida Kouhi Peter Conti [F]-2′ -Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (F-FMAU) in Prostate Cancer: Initial Preclinical Observations Molecular Imaging |
| title | [F]-2′ -Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (F-FMAU) in Prostate Cancer: Initial Preclinical Observations |
| title_full | [F]-2′ -Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (F-FMAU) in Prostate Cancer: Initial Preclinical Observations |
| title_fullStr | [F]-2′ -Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (F-FMAU) in Prostate Cancer: Initial Preclinical Observations |
| title_full_unstemmed | [F]-2′ -Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (F-FMAU) in Prostate Cancer: Initial Preclinical Observations |
| title_short | [F]-2′ -Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (F-FMAU) in Prostate Cancer: Initial Preclinical Observations |
| title_sort | f 2 fluoro 5 methyl 1 beta d arabinofuranosyluracil f fmau in prostate cancer initial preclinical observations |
| url | https://doi.org/10.2310/7290.2012.00004 |
| work_keys_str_mv | AT hosseinjadvar f2fluoro5methyl1betadarabinofuranosyluracilffmauinprostatecancerinitialpreclinicalobservations AT lipengyap f2fluoro5methyl1betadarabinofuranosyluracilffmauinprostatecancerinitialpreclinicalobservations AT ryanpark f2fluoro5methyl1betadarabinofuranosyluracilffmauinprostatecancerinitialpreclinicalobservations AT ziboli f2fluoro5methyl1betadarabinofuranosyluracilffmauinprostatecancerinitialpreclinicalobservations AT kaichen f2fluoro5methyl1betadarabinofuranosyluracilffmauinprostatecancerinitialpreclinicalobservations AT lindseyhughes f2fluoro5methyl1betadarabinofuranosyluracilffmauinprostatecancerinitialpreclinicalobservations AT aidakouhi f2fluoro5methyl1betadarabinofuranosyluracilffmauinprostatecancerinitialpreclinicalobservations AT peterconti f2fluoro5methyl1betadarabinofuranosyluracilffmauinprostatecancerinitialpreclinicalobservations |